linjc16/ctgov huggingface dataset:
Transverse Thoracic Plane Block in the Pediatric Cardiac Patient

Study Overview
=================
Brief Summary
-----------------
Postoperative pain after cardiothoracic surgery can be a significant problem interfering with recovery, yet difficult to manage due to the sedating effects of opiates. These patients frequently have associated postoperative pulmonary changes and are at risk of respiratory depression with opioid analgesia. The ultrasound-guided transversus thoracic muscle plane block (TTMPB) is a recently described regional anesthetic technique showing improvements in postoperative pain management. Further investigation is needed to establish the potential of the TTMPB as an analgesic modality in congenital cardiothoracic surgery in patients under the age of 18.

Official Title
-----------------
Transverse Thoracic Plane Block in the Pediatric Cardiac Patient

Conditions
-----------------
Pain, Acute, Congenital Heart Disease

Intervention / Treatment
-----------------
* Other: Transverse Thoracic Plane Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Congenital Heart Surgery Exclusion Criteria: Over 18

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Historical control patients that are matched to the surgery type | |
| Experimental<br>After the practice change of TTP was initiated, the future pediatric patients were put into a database. | Other: Transverse Thoracic Plane Block<br>* A bilateral plane block in the transverse thoracic space<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extubation | The amount of time until the patients are extubated in the ICU or OR. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical Stress Response | HR response to incision | 2 years | 
| Opiate Usage | Amount of total opiates used for the heart surgery | 2 years |
Glaucoma Screening With Smartphone Ophthalmology

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the accuracy and reliability of smartphone ophthalmoscopy compared to slit-lamp biomicroscopy in glaucoma screening for potential community screening programs.

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Other: optic nerve head ophthalmoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ocular hypertension glaucoma Exclusion Criteria: substantial media opacity refractive error outside the range from -10.00 to +5.00 diopters

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Glaucoma and Ocular Hypertension<br>Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy. | Other: optic nerve head ophthalmoscopy<br>* Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vertical cup-to-disc ratio |  | Up to 25 weeks from date of study initiation |
Identification of Stroke at the Emergency Medical Dispatch Center

Study Overview
=================
Brief Summary
-----------------
A study to investigate how stroke is identified and whether FAST, face-arm-speech test, is used in the emergency medical dispatch centre in Stockholm. The study will also investigate when FAST is used, does it increase the identification of stroke? And if other factors can be identified as markers for more effective identification of stroke during the emergency call.

Detailed Description
-----------------
Transcribed alarm calls are read through and analyzed using a qualitative method. Meaningful units are identified, coded and categorized. A phenomenological analysis is also applied to a separate analysis.

Official Title
-----------------
Identification of Stroke at the Emergency Medical Dispatch Center

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who has called the emergency medical dispatch centre and also are diagnosed as stroke at Södersjukhuset during the study period. Exclusion Criteria: Cases where needed documents and files are missing.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of stroke symptoms | A data collection tool assessing the frequency of stroke symptoms will be developed. The data collection tool will identify stroke symptoms presented by the caller during emergency calls and assess stroke symptoms in the Face-Arm-Speech-Time Test (FAST). Stroke symptoms will then be quantified into percentages for a descriptive analysis. | 1 h |
3D Imaging of Neonatal Faces

Study Overview
=================
Brief Summary
-----------------
Facial scans of newborns will be performed before and after implementation of respiratory support devices such as nasal CPAP. 3D scanned images will be processed by Fisher & Paykel Healthcare Limited. Images will be analyzed for changes or distortion in nasal structure.

Detailed Description
-----------------
Any newborns admitted to the neonatal intensive care unit at Sharp Mary Birch Hospital for Women and Newborns between 24-42 weeks CGA with parental informed consent are eligible. 3D scanned image will be obtained prior to implementation of nasal support devices and after nasal support devices. Fisher & Paykel Healthcare Limited will analyze the 3D images and observations will be made for changes in nasal structure or distortion.

Official Title
-----------------
3D Imaging of Neonatal Subjects

Conditions
-----------------
Nose Deformities, Acquired

Intervention / Treatment
-----------------
* Other: 3D Scan of nares


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants between 24 and 42 weeks corrected gestational age (inclusive) born at Sharp Mary Birch NICU, Signed informed consent form Exclusion Criteria: Nasally intubated infants Infants with craniofacial abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 24 Weeks
Maximum Age: 42 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Newborns requiring ncpap<br>3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks. | Other: 3D Scan of nares<br>* 3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Deformation changes in nares of preterm infants that require ncpap | 3D scans of infants face will be performed before implementation of NCPAP and a 3D scan will be performed after the NCPAP is discontinued and the images will be analyzed for changes in facial structures that might be due to NCPAP. | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
3-Dimensional, continuous positive airway pressure, nasal changes
Management of Post Endodontic Re-treatment Pain With Low-Level Laser Therapy

Study Overview
=================
Brief Summary
-----------------
In this clinical trial investigators aimed to evaluate Post endodontic re-treatment pain after irradiation of low level laser therapy

Detailed Description
-----------------
In this clinical trial, 61 patients requiring endodontic retreatments in the posterior teeth were selected. A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group. In the control group patients received placebo laser to eliminate the probable psychological effects of laser. Laser irradiation was done with a single dose of 808 nm wavelength (Whitening Lase II- Laser DMC, Samsung, Korea) with 100 mw power, and dose of 70 J/cm2 for 80 seconds. Pain severity was recorded before the treatment, immediately after the treatment and 4, 8, 12, 24 and 48 hours after the treatment by visual analogue scale (VAS). The pain scores were statistically analyzed by chi-square test between two groups. The effects of different variables on the post-operative pain experience were also studied by means of Logistic regression.

Official Title
-----------------
Management of Post Endodontic Re-treatment Pain With Low-Level Laser Therapy

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Device: low level laser
* Device: laser sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - patients requiring endodontic retreatments in the posterior teeth Exclusion Criteria: systemic diseases psychologic disorders
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: low level laser<br>A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group | Device: low level laser<br>* low level laser irradiation<br>|
| Placebo Comparator: laser sham<br>In the control group patients received placebo laser to eliminate the probable psychological effects of laser. | Device: laser sham<br>* laser without irradiation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction of pain after low level laser irradiation |  | baseline and 4, 8, 12, 24 and 48 hours after the treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endodontic retreatments, Low level laser, Pain
PK Study of Sildenafil in Neonate

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the pharmacokinetics of sildenafil which is used as treatment of pulmonary hypertension in neonate and preterm infant.

Official Title
-----------------
Pharmacokinetic Study of Sildenafil in Neonates and Preterm Infants

Conditions
-----------------
Neonates and Preterm Infants

Intervention / Treatment
-----------------
* Drug: Sildenafil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted at NICU in Seoul National University Hospital or Bundang Seoul National University hospital Infants who were diagnosed with PAH Exclusion Criteria: Severe allergic reaction to sildenafil Inotropics for hypotension within 3 days prior to enrollment AST or ALT > 3x ULN Any condition that would make the participant, in the opinion of the investigator, unsuitable for the stud

Ages Eligible for Study
-----------------
Maximum Age: 1 Month

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>sildenafil treatment | Drug: Sildenafil<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC(0-t) | 5 times drug level after 5 doses (pre30min/post 30min, 1hr, 2hr, 4hr) pharmacokinetics | t up to 5 weeks | 
| Cmax(0-t) | 5 times drug level after 5 doses (pre30min/post 30min, 1hr, 2hr, 4hr) pharmacokinetics | t up to 5 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in pulmonary arterial hypertension at 5 weeks | Echocardiography RV systolic pressure: TR velocity2 x 4 Septum contour: normal, flat at end-systole, flat at end-diastole LV shape: normal, partially D-shape, D-shape, squeezed LV eccentricity index RV area/LV area (Apical 4 chamber view, at end diastole) RA enlargement (Apical 4 chamber view) RV anterior wall thickness TAPSE (Tricuspid annular plane systolic excursion) RV Tei index (by tissue Doppler) Tissue Doppler velocity at RV free wall | pre, 2 weeks, 5 weeks of drug administration | 
| respiratory severity score | Mean airway pressure x FiO2 | pre, 2 weeks, 5 weeks after administration |
Ruxolitinib for Chuvash Polycythemia

Study Overview
=================
Brief Summary
-----------------
Chuvash polycythemia (CP) is a rare form of congenital polycythemia caused by mutations in the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent studies have demonstrated that VHL (von Hippel-Lindau tumor suppressor) regulates the activity of JAK2 (Janus kinase 2). In mouse models, inhibition of JAK2 reverses the CP phenotype. Therefore, the investigators hypothesize that JAK2 inhibition may have significant clinical benefits for CP patients.

Detailed Description
-----------------
Study involvement will last for 48 weeks. There will be approximately 11 visits through week 48. Visits may take up to 2-3 hours to complete and occur every 4 weeks for the first 24 weeks, then every 12 weeks until week 48. During each study visit, any or all of the following procedures may occur: List current medications and participant general health Obtain blood pressure, body weight, body temperature, respiratory rate and heart rate Measure Spleen by examination Obtain an abdominal MRI to evaluate spleen and any pre-existing or new blood clots Obtain blood samples for safety tests and to monitor kidney/liver function. Questionnaires for participant to complete regarding symptoms related to disease. Ruxolitinib dosing may be increased after 4 weeks if needed. The dose of the ruxolitinib may be reduced related to side effects.

Official Title
-----------------
Ruxolitinib for Chuvash Polycythemia

Conditions
-----------------
Erythrocytosis, Familial, 2

Intervention / Treatment
-----------------
* Drug: Ruxolitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Chuvash polycythemia Exclusion Criteria: Unable to comprehend or unwilling to sign an informed consent form.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ruxolitinib|Ruxolitinib 10 mg tablets twice daily|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Polycythemia
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)

Study Overview
=================
Brief Summary
-----------------
This study will validate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in Korean patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.

Official Title
-----------------
Multi-center, Prospective Cohort Study-II to Investigate the Impact of Comprehensive Geriatric Assessments on Survival and Toxicities in Elderly Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP (GERIAD2)

Conditions
-----------------
Lymphoma, Large B-cell, Diffuse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with newly diagnosed CD20+ DLBCL 65 years old or over Scheduled to receive R-CHOP chemotherapy Informed consent Exclusion Criteria: Other histology than CD20+ DLBCL Primary central nervous system DLBCL Patients with a diagnosis of cancer (other than basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, well differentiated thyroid cancer [papillary or follicular thyroid cancer]) within 3 years before the study entry or with any treatment for cancer within 3 years before entry Consent withdrawal

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Elderly DLBCL patients<br>Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-free survival | Event-free survival was defined as death, relapse from complete remission, progression during or after treatment, and discontinuation or changes of therapy during treatments | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 5 years | 
| Progression-free survival |  | 5 years | 
| Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
geriatric assessments, diffuse large B-cell lymphoma, activity of daily living, instrumental activity of daily living, Charlson's comorbidity index
Comparison of Different Portable Tonometers (Icare Pro, TONO-Pen AVIA, Perkins Tonometer, PASCAL Hand Held Dynamic Contour Tonometer)

Study Overview
=================
Brief Summary
-----------------
In different cases intraocular pressure (IOP) have to measured in lying position. Therefore a lot of portable tonometers have been established. The Icare Pro is a new tonometer on the market that allows faster and more comfortable IOP-measurements. No local anesthesia is needed, what is a major advantage for the patients. In this study the investigators want to evaluate if IOP measurements with Icare Pro Tonometer are as reliable as they are with other established portable tonometers (Perkins, TONO-Pen and hand held-Dynamic Contour Tonometer). Trial with medical device

Conditions
-----------------
Healthy Participants

Intervention / Treatment
-----------------
* Device: measurement of intraocular pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: healthy patients of at least 18 years of age or above Exclusion criteria: diagnosis of glaucoma or other optic neuropathies corneal disorder that make IOP measurement impossible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Study group<br>Study group | Device: measurement of intraocular pressure<br>* Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit<br>* Other names: PASCAL hand helt-Dynamic Contour Tonometer (Ziemer Ophthalmic Systems AG, Port, Switzerland);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraocular pressure | the intraocular pressure will be measured at the first and only study visit (Visit 1, day 0) | Study Visit 1 |